Physician profile
Boon Y Chew
NPI 1134221070
$6,415.27
in general payments reported to CMS, 2019-2025
54 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $375 · 2021: $1,201 · 2022: $929 · 2023: $1,146 · 2024: $1,047 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.76 |
| Education | $114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $887.33 | 2019-2025 | |
| Beigene, Ltd. | $525.00 | 2021 | |
| Genentech USA, INC. | $329.26 | 2019-2024 | Venclexta, Gazyva, Tecentriq |
| Amgen INC. | $311.37 | 2019-2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $301.59 | 2019-2025 | Iclusig, Fruzaqla |
| Genzyme Corporation | $279.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $264.76 | 2021-2025 | Enhertu, Calquence |
| Pfizer INC. | $254.65 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $245.45 | 2019-2024 | Opdivo |
| Glaxosmithkline, LLC. | $228.19 | 2020-2025 | Zejula, Jemperli, Blenrep |
| Lilly USA, LLC | $184.53 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $176.33 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $163.31 | 2019-2024 | Reblozyl, Opdualag |
| Taiho Oncology, INC. | $159.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $155.07 | 2022-2025 | Libtayo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boon Chew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.